Date Added: 14/09/2017
Date Updated: 14/09/2017
Prostate-specific membrane antigen radiopharmaceuticals for metastatic castration-resistant prostate cancer
Specialties: Oncology & radiotherapy - Radiology, imaging & nuclear medicine - Renal disease & urology
Technology Type: Drugs
Stage of development: Investigational - phase III
Stage of EAA: Assessment Complete
HealthPACT noted that Lutetium-177 may represent a promising additional treatment option for metastatic castration-resistant prostate cancer. Although studies to date have primarily reported good patient response rates and reductions in prostate specific antigen levels, there is little evidence as to how this translates into improved patient overall survival or quality of life.
HealthPACT considers that further evidence in relation to the patient experience with this treatment and patient outcomes is required before the Lutetium-177 is considered suitable for clinical practice. If Lutetium-177 is further proposed as a complement or substitute to existing treatment standards, high-quality comparative clinical studies will be required.